<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melarsoprol (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melarsoprol (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Melarsoprol (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="126253" href="/d/html/126253.html" rel="external">see "Melarsoprol (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information"</a> and <a class="drug drug_patient" data-topicid="126405" href="/d/html/126405.html" rel="external">see "Melarsoprol (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F54012909"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiprotozoal</span></li></ul></div>
<div class="block dop drugH1Div" id="F54012923"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d4ee2af-60d2-454f-988c-8a9cd4c675ce">African trypanosomiasis, second-stage disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>African trypanosomiasis (sleeping sickness), second-stage disease (with CNS involvement): Note:</b> Melarsoprol is only available through special distribution programs; refer to <b>Prescribing and Access Restrictions</b> for additional information. Dosing guidance is provided in the investigational new drug (IND) protocol when drug is released by the CDC. Use concomitantly with prednisolone to reduce the risk of melarsoprol-related encephalopathy; various prednisolone regimens have been reported; optimal dose has not been defined; doses are typically administered once daily for 10 to 12 days (Burri 2000; WHO 2019; MSF 2019); initiation of prednisolone for several days prior to melarsoprol has been suggested (Pépin 1989; Pépin 2006); some experts have recommended tapering the dose over 3 to 6 days (Pépin 2006; Schmid 2005; WHO 2019); an alternate approach for prolonged regimens is prednisolone administration only on days on which melarsoprol is administered (Burri 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">Due to <i>Trypanosoma brucei rhodesiense</i>: Limited data available.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Abbreviated 10-day regimen:</i> Infants, Children, and Adolescents: IV: 2.2 mg/kg/dose once daily for 10 days; maximum dose: 180 mg/dose. Use concomitantly with prednisolone to reduce the risk of melarsoprol-related encephalopathy (Kuepfer 2012; MSF 2019; <i>Red Book</i> [AAP 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prolonged discontinuous regimen</i>: Infants, Children and Adolescents: IV: 2 to 3.6 mg/kg/dose once daily for 3 days, initiating at 2 mg/kg/dose on day 1 and titrating up to 3.6 mg/kg/dose on day 3, followed by a 7-day drug free interval; then a second series consisting of 3.6 mg/kg/dose once daily for 3 days, followed by a 7-day drug free interval; and then a final series of 3.6 mg/kg/dose once daily for 3 days; maximum dose: 180 mg/dose (CDC 2019; Pépin 2006). Use concomitantly with prednisolone to reduce the risk of melarsoprol-related encephalopathy (CDC 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Due to <i>Trypanosoma brucei gambiense</i> (alternative agent): Limited data available: Infants, Children, and Adolescents: IV: 2.2 mg/kg/dose once daily for 10 days; maximum dose: 180 mg/dose. Use concomitantly with prednisolone to reduce the risk of melarsoprol-related encephalopathy (Burri 2000; Eperon 2007; WHO 2019).</p></div>
</div>
</div>
<div class="block doa drugH1Div" id="F53870277"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="126253" href="/d/html/126253.html" rel="external">see "Melarsoprol (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d4ee2af-60d2-454f-988c-8a9cd4c675ce">African trypanosomiasis, second-stage disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>African trypanosomiasis, second-stage disease (with CNS involvement):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Due to <i>T. b. rhodesiense: </i>
<b>IV:</b> 2 to 3.6 mg/kg once daily for 3 days (dose is progressively increased during this course); after 7 days, 3.6 mg/kg once daily for 3 days, followed by another course of 3.6 mg/kg once daily for 3 days, starting 7 days after completion of the previous course for a total of 3 courses (CDC 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Due to <i>T. b. gambiense </i>(alternative agent)<i>: </i>
<b>IV:</b> 2.2 mg/kg (maximum dose: 180 mg) once daily for 10 days (Burri 2000; WHO 2019).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F53791847"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac insufficiency, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Encephalopathy, headache, hyperthermia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Jarisch-Herxheimer reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency</p></div>
<div class="block coi drugH1Div" id="F53870267"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">G6PD deficiency (Kappagoda 2011); pregnancy (depending on the condition of the mother) (WHO 2019).</p></div>
<div class="block war drugH1Div" id="F53870268"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Encephalopathy: Reactive encephalopathy, sometimes fatal, may occur, usually within 7 to 14 days after treatment initiation. Presentation includes abnormal behavior, cerebral edema, seizures, progressive coma, or rapid onset of neurological disorders. Closely monitor patients; fever and/or headache may be early signs of the disorder (Blum 2001; WHO 2019). Discontinue treatment if signs/symptoms of encephalopathy occur; administration of corticosteroids may prevent development of this syndrome (Pépin 1989).</p>
<p style="text-indent:-2em;margin-left:4em;">• Irritant: Melarsoprol is an irritant; avoid extravasation (WHO 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol (MSF 2016; WHO 2019); large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54012917"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol (MSF 2016; WHO 2019); in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block accres drugH1Div" id="F53870260"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Melarsoprol is not commercially available in the US; it is available for the treatment of patients with African trypanosomiasis through the Centers for Disease Control (CDC) Drug Service to be used under an Investigational New Drug (IND) protocol. To obtain treatment advice and obtain melarsoprol, contact the Division of Parasitic Diseases and Malaria (404-718-4745; <a class="__cf_email__" data-cfemail="c0b0a1b2a1b3a9b4a5b380a3a4a3eea7afb6" href="/cdn-cgi/l/email-protection">[email protected]</a>), the CDC Drug Service (404-639-3670; <a class="__cf_email__" data-cfemail="294d5b5c4e5a4c5b5f404a4c694a4d4a074e465f" href="/cdn-cgi/l/email-protection">[email protected]</a>), or for emergencies after business hours, on weekends, and on federal holidays, the CDC Emergency Operations Center (770-488-7100). Additional information from the CDC is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flaboratory%2Fdrugservice%2Fformulary.html&amp;token=8fUMx%2BfB4trlY8x%2FMo8Y9Ddj5kItZ1H7qlW%2Fe3GJptY28xGubTU0DXWzUi5nl8%2BCwNhzfAcY95p7Mq5fGdd6Fg%3D%3D&amp;TOPIC_ID=126626" target="_blank">https://www.cdc.gov/laboratory/drugservice/formulary.html</a>.</p></div>
<div class="block admp drugH1Div" id="F54012927"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer undiluted by slow IV push (MSF 2019; WHO 2019). When drawing up dose at the bedside, drug should not come into contact with water; may lead to precipitation. Glass syringes are preferred for administration; following use, syringe must be washed, dried, and sterilized. If sterilization of glass syringe is not possible or reliable, then plastic syringes may be used; however, administration should occur immediately after drawing into syringe as melarsoprol may lead to deterioration of some plastic syringes (MSF 2016; WHO 2019). Some experts recommend administration via a microprofuser (butterfly) (WHO 2019). Melarsoprol is an irritant; avoid extravasation (WHO 1995).</p></div>
<div class="block adm drugH1Div" id="F53870278"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer by slow IV injection (WHO 2019). Melarsoprol is an irritant; avoid extravasation (WHO 1995).</p></div>
<div class="block sts drugH1Div" id="F53870270"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Protect from light (WHO 1995).</p></div>
<div class="block usep drugH1Div" id="F54012912"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of second-stage African trypanosomiasis (sleeping sickness), with involvement of the CNS, due to <i>Trypanosoma brucei rhodesiense</i> or <i>Trypanosoma brucei gambiense</i>. <b>Note: </b>Melarsoprol is only available through the CDC for patients meeting Investigational New Drug eligibility criteria; contact CDC for details.</p></div>
<div class="block cyt drugH1Div" id="F53808781"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53808778"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F53870266"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Other agents are preferred for the treatment of West African trypanosomiasis in pregnant women when therapy cannot be postponed until after delivery. Melarsoprol is theoretically contraindicated for use during pregnancy, depending on the condition of the mother (WHO 2019).</p></div>
<div class="block mopp drugH1Div" id="F54012928"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions; encephalopathy signs/symptoms (eg, fever, headache, tremor); extravasation; phlebitis; blood pressure; serum albumin; cardiac, renal, and hepatic function (CDC 2019; WHO 1995; WHO 2019).</p></div>
<div class="block pha drugH1Div" id="F53870271"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Organoarsenic compound that acts on trypanothione (Fairlamb 1989).</p></div>
<div class="block phk drugH1Div" id="F53870272"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: &gt;100 L (Burri 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized to active metabolite, melarsen oxide (Nok 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 35 hours (Burri 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 15 minutes (Nok 2003).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11348533">
<a name="11348533"></a>Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. <i>Trop Med Int Health</i>. 2001;6(5):390-400. doi: 10.1046/j.1365-3156.2001.00710.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/11348533/pubmed" id="11348533" target="_blank">11348533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8391966">
<a name="8391966"></a>Burri C, Baltz T, Giroud C, Doua F, Welker HA, Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. <i>Chemotherapy</i>. 1993;39(4):225-234. doi: 10.1159/000239130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/8391966/pubmed" id="8391966" target="_blank">8391966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10791526">
<a name="10791526"></a>Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. <i>Lancet</i>. 2000;355(9213):1419-1425. doi: 10.1016/S0140-6736(00)02141-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/10791526/pubmed" id="10791526" target="_blank">10791526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Parasites - African trypanosomiasis (also known as sleeping sickness): Resources for health professionals. Updated June 6, 2019. Accessed October 25, 2019. <a href="https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17207760">
<a name="17207760"></a>Eperon G, Schmid C, Loutan L, Chappuis F. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. <i>Acta Trop</i>. 2007;101(1):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/17207760/pubmed" id="17207760" target="_blank">17207760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2704738">
<a name="2704738"></a>Fairlamb AH, Henderson GB, Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. <i>Proc Natl Acad Sci U S A</i>. 1989;86(8):2607-2611. doi: 10.1073/pnas.86.8.2607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/2704738/pubmed" id="2704738" target="_blank">2704738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21628620">
<a name="21628620"></a>Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. <i>Mayo Clin Proc</i>. 2011;86(6):561-583. doi: 10.4065/mcp.2011.0203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/21628620/pubmed" id="21628620" target="_blank">21628620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22970329">
<a name="22970329"></a>Kuepfer I, Schmid C, Allan M, et al. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. <i>PLoS Negl Trop Dis</i>. 2012;6(8):e1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/22970329/pubmed" id="22970329" target="_blank">22970329</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Medecins Sans Frontieres (MSF). Clinical guidelines. Diagnosis and treatment manual for curative programmes in hospitals and dispensaries. Guidance for prescribing, 2019 edition. Available at: https://medicalguidelines.msf.org/msf-books-hosting/14385582-English.pdf. Accessed January 13, 2020.</div>
</li>
<li>
<div class="reference">
                  Medecins Sans Frontieres (MSF). Essential drugs: practical guide intended for physicians, pharmacists, nurses and medical auxiliaries, 2016 edition. Available at: http://refbooks.msf.org/msf_docs/en/essential_drugs/ed_en.pdf. Accessed January 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12743807">
<a name="12743807"></a>Nok AJ. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. <i>Parasitol Res</i>. 2003;90(1):71-79. doi: 10.1007/s00436-002-0799-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/12743807/pubmed" id="12743807" target="_blank">12743807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2566790">
<a name="2566790"></a>Pépin J, Milord F, Guern C, Mpia B, Ethier L, Mansinsa D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. <i>Lancet</i>. 1989;1(8649):1246-1250. doi: 10.1016/s0140-6736(89)92340-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/2566790/pubmed" id="2566790" target="_blank">2566790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16483622">
<a name="16483622"></a>Pépin J, Mpia B. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. <i>Trans R Soc Trop Med Hyg</i>. 2006;100(5):437-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/16483622/pubmed" id="16483622" target="_blank">16483622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15871127">
<a name="15871127"></a>Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). <i>J Infect Dis</i>. 2005;191(11):1922-1931.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/15871127/pubmed" id="15871127" target="_blank">15871127</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). <i>WHO Model Prescribing Information: Drugs Used in Parasitic Diseases</i>. 2nd ed. Geneva, Switzerland: World Health Organization; 1995.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO)/Department of Control of Neglected Tropical Diseases. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva, Switzerland: World Health Organization; 2019. https://www.who.int/trypanosomiasis_african/resources/9789241550567/en. Accessed October 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/melarsoprol-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126626 Version 16.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
